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Lack of Suppressive CD4þCD25þ FOXP3þ T Cells
in Advanced Stages of Primary Cutaneous T-Cell
Lymphoma
Machteld M. Tiemessen1, Tracey J. Mitchell2, Lisa Hendry1, Sean J. Whittaker2, Leonie S. Taams1,3
and Susan John1,3
Mycosis fungoides and its leukemic variant, Sezary syndrome, are the most common primary cutaneous T-cell
lymphomas (CTCLs). In an ex vivo study, we investigated the percentage, phenotype, and suppressive function
of CD4þCD25þ regulatory T cells (Tregs) from peripheral blood of CTCL patients. The percentage of Tregs did
not differ significantly between patients and controls. Functional assays demonstrated a dichotomy in Treg
function: in four out of 10 patients CD4þCD25þ T cells were incapable of suppressing autologous
CD4þCD25 T-cell proliferation, whereas suppressive function was intact in the other six patients. Suppressive
activity of Tregs inversely correlated with the peripheral blood tumor burden. T-plastin gene expression, used as
a Sezary cell marker, confirmed that Sezary cells were heterogeneous for CD25 expression. Mixed lymphocyte
reactions demonstrated that CD4þCD25 T cells from patients who lacked functional Tregs were susceptible to
suppression by Tregs from healthy controls, and had not become suppressive themselves. Furthermore, we
found reduced expression of Foxp3 in the CD4þCD25þ Tregs of these patients relative to the other six CTCL
patients and controls. Our findings thus indicate a dysfunction of peripheral Tregs in certain CTCL patients,
which correlates with tumor burden.
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INTRODUCTION
Primary cutaneous T-cell lymphoma (CTCL) comprises a
heterogeneous group of extranodal non-Hodgkin’s lympho-
mas, representing 2% of all lymphomas and occurs at an
annual incidence of 0.3–1 per 100,000 persons (Weinstock
and Gardstein, 1999). Mycosis fungoides and its leukemic
variant, Sezary syndrome, are the most frequent CTCLs
involving the skin. Mycosis fungoides presents with a skin-
restricted infiltration of clonal T cells and an indolent course.
Sezary syndrome represents an aggressive form of CTCL and
is characterized by a diffuse pruritic erythroderma, lympha-
denopathy, and the presence of a clonal proliferation of
malignant T cells in the peripheral blood, skin, and lymph
nodes. Malignant T cells in Sezary syndrome represent a
clonal expansion of mature helper T cells with a memory
phenotype (Kim et al., 2005). Generally, CTCL cells appear to
proliferate poorly in vitro and it is still unclear what
mechanisms are adopted by CTCLs in vivo to allow
expansion and escape immune surveillance. The dysregula-
tion of the STAT proteins, Stat3 and Stat5, in CTCL may be
one mechanism adopted by malignant T cells to promote
survival (Brender et al., 2001; Mitchell et al., 2003). Recently,
in vitro proliferation of CD4þ T cells from CTCL patients, for
up to 3 months, was demonstrated by co-culture of these cells
with autologous immature dendritic cells loaded with
apoptotic CD4þ T cells. The patient T cells cultured in this
manner were shown to adopt a CD4þCD25þ T-regulatory
(Treg) phenotype (Berger et al., 2005).
Naturally occurring CD4þCD25þ Tregs are specialized
CD4þ T cells, which express high levels of CD25, and
whose main function is to suppress the activity of other
immune cells, thus maintaining immunological tolerance
(Shevach, 2002). In humans, like in mice, these Tregs
comprise 5–10% of CD4þ T cells in peripheral blood
(Taams et al., 2001), are identified by the selective expression
of a transcription factor, Foxp3 (Ramsdell, 2003), and express
high levels of the inhibitory receptor, CTLA-4 (Read et al.,
2000; Taams et al., 2001). In vitro studies have shown that
CD4þCD25þ Tregs are anergic and do not proliferate in
response to anti-CD3 mAb or antigenic stimulation (Levings
et al., 2001; Taams et al., 2001, 2002). Whereas the presence
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of Tregs is clearly beneficial for the prevention of auto-
immunity, in the case of tumor biology, the presence of these
cells could diminish effective natural tumor surveillance and
clearance. Indeed, several studies have suggested that tumor
progression might be associated with an increase in
CD4þCD25þ Tregs (reviewed by Terabe and Berzofsky,
2004). Based on the study by Berger et al. (2005) and our own
observations that malignant CD4þ T cells in CTCLs are
generally anergic, we investigated whether this unrespon-
siveness was associated with an increase in CD4þCD25þ
Treg percentage or function.
RESULTS
Anergy in CD4þ T cells from CTCL patients is not associated
with an overall increase in the percentage of CD4þCD25þ
T cells
We first investigated the proliferative capacity of CD4þ
CTCL T cells. CD4þ T cells from CTCL patients displayed
significantly less proliferation in response to anti-CD3 mAb
and irradiated antigen-presenting cells (APCs) than CD4þ
T cells isolated from healthy controls (HCs) (Figure 1a). We
hypothesized that this observed anergy may be caused by the
conversion of malignant CD4þ T cells into CD4þCD25þ
Tregs, as suggested by a recent study (Berger et al., 2005).
Therefore, we investigated the percentage of CD4þCD25þ
T cells in the CD4þ T-cell population of patients by
immunophenotyping for CD4 and CD25 expression. Figure
1b shows a representative dot plot for CD4 and CD25
staining in peripheral blood lymphocytes from an HC and a
CTCL patient. The boxed region indicates the percentage of
CD4þCD25bright cells, which have been suggested to
contain the most effective regulatory T cells (Baecher-Allan
et al., 2001). As expected, CTCL patients had a dramatic
expansion of CD4þ T cells in the peripheral blood (Figure
1b and Table 1). However, no significant difference was
observed between the mean percentage of CD4þCD25þ or
CD4þCD25bright T cells present in the CD4þ T-cell
population: 9.270.5 vs 9.774% of CD4þCD25þ T cells
and 1.470.3 vs 1.970.9% of CD4þCD25bright T cells in
HCs and CTCLs, respectively (Figure 1c). Together, these data
show that in CTCL patients the anergic phenotype of CD4þ
T cells is not accompanied by an increased percentage of
CD4þCD25þ total or CD4þCD25þ bright T cells.
CTCL patients with a high tumor burden contain dysfunctional
CD4þCD25þ regulatory T cells
We next investigated whether the anergic phenotype of
CD4þ T cells in CTCL patients was owing to an overall
increase in suppressive function of the CD4þCD25þ Tregs.
Therefore, we examined the suppressive effects of
CD4þCD25þ T cells on CD4þCD25 T-cell proliferation
upon stimulation with anti-CD3 mAb and autologous APC.
CD4þCD25þ and CD4þCD25 T cells from HC and
CTCL patients were isolated with similar efficiency and purity
(Figure 2a and b). Surprisingly, when tested functionally, in
four of the 10 CTCL patients, the isolated CD4þCD25þ
T cells did not suppress the CD4þCD25 T-cell proliferation
(representative graph in Figure 2c and Table 1, patients 1–4),
whereas intact suppressive activity of the CD4þCD25þ
T cells was observed in the other six CTCL patients (Figure 2c
and Table 1, patients 5–10). Thus, functional characterization
of Tregs revealed a distinct classification of CTCL patients
into those with suppressive and those with non-suppressive
CD4þCD25þ Tregs. Interestingly, we observed that the
four CTCL patients with non-functional CD4þCD25þ T
cells had a significantly enhanced Sezary cell count (49711
vs 772%, P¼ 0.0061) and total lymphocyte count
(2074 109/l vs 471109/l, P¼ 0.0095) compared to the
patients with intact Treg-suppressive capacity (see also
Table 1). Indeed, we found a significant negative correlation
between markers of tumor burden and the level of suppres-
sion by CD4þCD25þ Tregs (R¼0.757, 0.935, and
0.650 for the total lymphocyte count, Sezary count, and
percentage CD4þ T cells, respectively, Po0.05, data not
shown). Thus, a loss of Treg activity is significantly associated
with increasing peripheral blood tumor burden.
Non-functional CD4þCD25þ Tregs display a significantly
lower expression of Foxp3 mRNA expression in comparison to
functional CD4þCD25þ Tregs
The four CTCL patients who contained the non-suppressive
CD4þCD25þ T cells (patients 1–4) also contained a
significantly lower percentage of CD4þCD25þ total and
CD4þCD25bright T cells as compared to the HCs (2.470.8%
of CD4þCD25þ and 0.1370.06% of CD4þCD25bright
cells, Po0.05). As both the presence of Foxp3 and CTLA-4
have been associated with CD4þCD25þ Treg function,
we next evaluated the expression of these genes in
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Figure 1. The anergic phenotype of CD4þ T cells from CTCL patients is not
owing to an overall increase in CD4þCD25þ T cells. CD4þ T cells were
isolated from PBMC of HC and CTCL patients via MACS. (a) CD4þ T cells
were stimulated with anti-CD3 mAb (50 ng/ml) and APC, and T-cell
proliferation was measured by 3H-thymidine incorporation. Data are depicted
as mean c.p.m.7SEM, n¼10 independent experiments. (b) Representative
dot plots of peripheral blood lymphocytes from HC versus a CTCL patient
showing the percentage of CD4þCD25þ total and CD4þCD25þ bright T
cells in CD4þ T cells; the square region indicates CD4þCD25bright T cells.
(c) The percentages of CD4þCD25þ total and CD4þCD25þ bright T cells in
the CD4þ T-cell fraction are shown for each individual HC and CTCL
patient.
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CD4þCD25 and CD4þCD25þ T cell subsets by real-
time PCR analysis. In HC, Foxp3 and CTLA-4 mRNA
expression was significantly enhanced in CD4þCD25þ
T cells compared to CD4þCD25 T cells (Figure 3). In CTCL
patients with dysfunctional CD4þCD25þ Tregs (non-
suppressive), the relative expression of Foxp3 mRNA was
significantly decreased in the purified CD4þCD25þ T-cell
subset as compared to CD4þCD25þ T cells from HC and
CTCL patients with intact Treg activity (suppressive) (Figure 3).
The relative expression of CTLA-4 was also decreased in
CD4þCD25þ T cells from the non-suppressive CTCL
patients as compared to HC and suppressive CTCL patients,
but this was not significant (Figure 3). We used the Sezary
cell-specific marker T-plastin (Su et al., 2003; Nebozhyn
et al., 2006) to identify the cell populations containing tumor
cell-derived mRNA (Figure 3c). Consistent with previously
published data (Lin et al., 1999; Su et al., 2003; Nebozhyn
et al., 2006), no T-plastin expression was observed in RNA
isolated from the T cells of HC. However, T-plastin was
detected in 8/10 CTCL patients both in the suppressive and
non-suppressive group and in both T-cell populations. These
data demonstrate that the tumor-derived cells display a
distinct heterogeneity in CD25 expression. Together, these
results indicate that the dysfunctional CD4þCD25þ Tregs from
CTCL patients showed a concomitant decrease in Foxp3 ex-
pression and that the tumor cells were not exclusively CD25þ .
The defect in Treg-mediated suppression lies within the
CD4þCD25þ T-cell subset
We investigated whether the defective suppression was
owing to a defect in the CD4þCD25þ or in the CD4þ
CD25 T-cell population. Therefore, mixed lymphocyte
Table 1. CD4+CD25+ Treg activity and markers of peripheral blood tumor burden in CTCL patients
CTCL
1 2 3 4 5 6 7 8 9 10 HC (n=10)
CTCL SzS SzS SzS SzS SzS SzS SzS SzS MF MF —
Months since diagnosis1 21 1 5 1 36 6 1 4 1 16 —
Treatment2 ECP ECP ECP ECP ECP ECP ECP ECP ECP ECP —
Tar Tar/IFN
Suppression by Tregs (%)3 0 0 0 0 65 89 66 76 92 99 5777
Sezary cell count (%)4 71 43 20 63 12 9 7 10 0 0 —
CD4+ T-cell count (%)5 88 81 54 85 62 56 27 70 39 42 3073
Total lymphocyte count (109/l)6 23 30 11 18 4.1 4.3 6.2 4.5 1.5 5.3 —
The table shows clinical data and Treg function for each CTCL patient (no. 1–10). Patients were diagnosed as either SzS or MFs.
1Patients samples were taken at the indicated number of months after diagnosis.
2Patients were treated with extracorporeal photopheresis (ECP), in some cases in combination with Targretin (Tar), or Interferon alpha2B (IFN).
3Percentage suppression by CD4+CD25+ Tregs was measured by calculating the inhibition of CD4+CD25 T-cell proliferation in the presence of
CD4+CD25+ Tregs.
4Sezary cell count in the lymphocyte population was estimated by counting the number of atypical lymphocytes with cerebriform nuclei (Sezary cells) in
blood smears.
5The percentage CD4+ T cells in PB lymphocytes was measured via flow cytometry by gating on lymphocytes and CD4+ T cells.
6Total lymphocyte count was assessed flow cytometry.
Data on the healthy controls are averages7SEM of 10 independent experiments.
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Figure 2. Dichotomy in suppressive activity of CD4þCD25þ Tregs from
CTCL patients. (a) CD4þCD25þ T cells were isolated from phosphate
buffer from HC and CTCL patients by MACS. Representative dot plots
show the percentage CD4þCD25þ T cells from HC and CTCL patients
before and after purification. (b) The relative mRNA expression of CD25 in
purified CD4þCD25 and CD4þCD25þ T-cell subsets from HC and
CTCL patients was determined by real-time PCR. Results are shown as the
mean7SEM of eight independent experiments. (c) Isolated CD4þCD25
T cells were cultured with anti-CD3 mAb and irradiated autologous
PBMC in the absence (black bars, 1:0 ratio) or presence (open bars, 1:1 ratio)
of autologous CD4þCD25þ T cells. Results of three representative
independent experiments are shown: one CTCL patient with
non-suppressive CD4þCD25þ T cells (CTCL3), one CTCL patient
with suppressive CD4þCD25þ T cells (CTCL6), and one representative
HC (HC9).
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reactions were performed in which responder T cells from a
healthy donor were co-cultured with APC derived from a
CTCL patient, in the absence or presence of CD4þCD25 or
CD4þCD25þ T cells from the same CTCL patient. In this
allogeneic setting, the CD4þCD25þ T cells from the non-
suppressive CTCL patients induced substantially lower
suppression (30%, Figure 4a) compared to CD4þCD25þ
T cells from HC (80%, Figure 4c) or from ‘‘suppressive’’ CTCL
patients (60%, Figure 4b). The CD4þCD25 T cells from
both non-suppressive and suppressive CTCL patients showed
only weak, if any, capacity to suppress T-cell proliferation (17
and 2%, Figure 4a and b), indicating that the CD4þCD25
T-cell population had not acquired suppressive activity.
Figure 4c demonstrates that in contrast to the anergy
observed in Figure 1, CD4þCD25 T cells from
CTCL patients were able to proliferate under strong stimula-
tory conditions as provided by allogeneic stimulation. In
addition, Figure 4c shows that the CD4þCD25 T cells
from CTCL patients who lacked Treg-mediated suppression
are susceptible to suppression by CD4þCD25þ T cells
from HCs. Together, these data indicate that the defect
in Treg-mediated regulation in the non-suppressive
CTCL patients is not owing to an intrinsic defect in the
susceptibility of the CD4þCD25 T-cell population to
suppression, but rather that the defect lies in the CD4þ
CD25þ T cells.
DISCUSSION
Disease progression in advanced stages of CTCL is character-
ized by a marked shift in the host immune system to one that
is more suppressive and less cytotoxic (Kim et al., 2005).
A recent study suggested that tumor cells in CTCL can be
induced to adopt a Treg phenotype and function using an in
vitro photopheresis model (Berger et al., 2005). Therefore, it
seemed plausible that there may be an increase in the relative
number and/or activity of peripheral Tregs in CTCL patients.
Our results on 10 CTCL patients, however, demonstrate no
significant increase in the percentage of CD4þCD25þ or
CD4þCD25bright T cells in the peripheral blood as compared
to HCs. These data indicate that the significantly reduced
proliferation of malignant CD4þ T cells in CTCL patients
to TCR-activating stimuli is not attributed to the conversion
of these cells into classical CD4þCD25þ Tregs in the
periphery.
Interestingly, our functional assays indicate a striking
dichotomy in our patient cohort: one group that does not
contain suppressive CD4þCD25þ Tregs, called ‘‘non-
suppressive CTCL’’, and one group that has CD4þCD25þ
Tregs with suppressive capacity (denominated ‘‘suppressive
CTCL’’). Importantly, this dichotomy in Treg function
correlates with typical markers of peripheral blood tumor
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Figure 3. Lack of suppressive function in CD4þCD25þ Tregs in CTCL
patients is associated with significantly lower Foxp3 mRNA expression.
(a) The relative mRNA expression levels of Foxp3 , (b) CTLA-4, and
(c) T-plastin in CD4þCD25 and CD4þCD25þ T cells were assessed by
real-time PCR. The mean7SEM of the mRNA expression is shown for HCs
(n¼8), suppressive CTCL patients (n¼ 4), and non-suppressive CTCL patients
(n¼4). Significant differences are indicated in the figures; ND, not detected.
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Figure 4. The defect in Treg-mediated regulation lies within the
CD4þCD25þ T-cell population. CD4þCD25þ or CD4þCD25 T cells
from (a) non-suppressive or (b) suppressive CTCL patients were tested for their
capacity to suppress the proliferation of allogeneic T cells derived from HC.
CD4þCD25 HC T cells were cultured alone (black bars, 1:0), in the
presence of CD4þCD25þ CTCL T cells (white bars, 1:1 ratio) or
CD4þCD25 CTCL T cells (hatched bars, 1:1 ratio). (c) CD4þCD25
T-cells from a non-suppressive patient were cultured in the absence (black
bar, 1:0) or presence of allogeneic CD4þCD25þ T cells derived from HC
(white bar, 1:1 ratio). The suppressive activity is indicated by percentage
inhibition in each graph. The intrinsic suppressive activity of the
CD4þCD25þT cells in the corresponding autologous system were 0, 89,
and 40% for non-suppressive CTCLs, suppressive CTCLs, and HCs,
respectively. One of the two independent experiments is shown.
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burden: that is, the non-suppressive CTCL patients have
significantly increased counts of CD4þ T cells, total
lymphocytes, and Sezary cells as compared to the suppres-
sive CTCL group. Consistent with the significant correlation
between tumor burden and loss of functional Tregs, we
observed that the two erythrodermic mycosis fungoides
patients (CTCLs 9 and 10) were extremely potent in the
suppression assay, resulting in 92 and 99% suppression of
T-cell proliferation, respectively. The dichotomy in Treg
function furthermore illustrates that the lack of suppressive
capacity in the severe CTCL patients was not owing to their
higher average age (6674 years) compared to controls
(3873 years), as suggested recently (Tsaknaridis et al.,
2003), as intact suppression was observed in the other six
CTCL patients who were of similar age (6573 years). Also,
other recent studies demonstrate intact CD4þCD25þ Treg
function in the elderly (470 years) and the young (o35
years), with similar expression of CTLA-4 (Gregg et al., 2005)
and Foxp3 (AN Akbar, personal communication).
Sezary cells can be identified by the expression of cell
surface markers such as CD40, CD40 ligand (Storz et al.,
2001), and SC5 (Nikolova et al., 2001, 2002). However, the
potential use for these molecules to isolate Sezary cells is
limited by the fact that they are also found on some normal
cells in the peripheral blood. The use of specific TCRVb chain
antibodies as an alternative approach is limited by the lack of
available mAb reacting with some TCRVDJb gene products in
the blood (Bigler et al., 1996; Langerak et al., 2001).
Although it was not possible to isolate directly intact tumor
cells based on cell surface marker expression for functional
evaluation, we were able to demonstrate the presence of
Sezary cells in both CD4þCD25 and CD4þCD25þ
T-cell subsets using the recently described Sezary cell marker
T-plastin (Su et al., 2003; Nebozhyn et al., 2006), which is
predominantly a cytoplasmic protein that functions to
regulate actin assembly and cellular motility. The detection
of T-plastin mRNA expression confirmed that peripheral
blood tumor cells display a distinct heterogeneity in terms of
T-cell phenotypic cell surface marker expression, as both the
CD25 and CD25þ cells expressed T-plastin regardless of
Treg function.
We found that the lack of function of CD4þCD25þ
Tregs in the non-suppressive CTCL group was not owing to
decreased susceptibility to suppression in the CD4þCD25
responder T cells, nor had suppressive activity shifted towards
these cells. Instead, the dysfunction appears to lie in the
CD4þCD25þ Treg subset, which coincides with a sig-
nificantly lower expression of Foxp3 compared to HCs.
Foxp3 gene expression has been detected in adult T-cell
lymphoma, which is also characterized by a clonal prolifera-
tion of CD4þCD45ROþ tumor cells, albeit with consis-
tently higher CD25 expression and increased numbers of
CD4þCD25þ Tregs as compared to CTCLs (Karube et al.,
2004; Walsh et al., 2006). Interestingly, a recent study in
multiple myeloma patients described similar findings to
our study, that is, a decrease in the percentage of
CD4þCD25þ FOXP3þ T cells with a concomitant
decrease in suppressive activity (Prabhala et al., 2006),
suggesting that this phenomenon might contribute to
dysfunctional T-cell responses in other hematological malig-
nancies as well. The same paper showed that increasing the
ratio of CD4þCD25þ T cells to responder cells did not
compensate for the lack of suppression.
Besides a lack of Foxp3, other mechanisms might
contribute to the observed functional dysregulation of
CD4þCD25þ T cells in the non-suppressive patients. As
survival and function of CD4þCD25þ T cells is highly
dependent on the production of IL-2 by neighboring T cells
(Malek and Bayer, 2004), a low level of IL-2, as reported in
CTCL patients (Dummer et al., 1992) might trigger apoptosis
of CD4þCD25þ T cells (Taams et al., 2001). Notably, we
did observe a high percentage of non-viable CD4þCD25þ
T cells (30–50%, as measured by trypan blue stain, data
not shown) in three out of the four non-suppressive CTCL
patients, a feature that was found in only one out of
six suppressive patients. Additionally, a lack of efficient
IL-2 signalling in CTCL patients (Mitchell et al., 2003)
may contribute to lower relative numbers of peripheral
Tregs.
Surprisingly, CTLA-4 gene expression appeared increased
in the CD4þCD25 population of non-suppressive patients
as compared to suppressive CTCL patients (Figure 3b). This is
consistent with a recent study showing a direct correlation
between disease stage/progression in CTCL and increased
expression of CTLA-4 (Wong et al., 2006). In view of the
observed T-plastin expression in both CD25 and CD25þ
T-cell subsets, it would seem likely that this represents
increased tumor cell expression of CTLA-4 with increasing
peripheral blood tumor burden, albeit with an unexplained
restriction to the CD25 population. The mechanism and
functional consequences remain unclear, although it has
been postulated that tumor-derived CTLA-4 might suppress
the proliferation of normal T cells, whereas defective CTLA-4
signalling pathways in the tumor cell, notably owing to a
dysregulation of AP1 detected previously in CTCL (Mao et al.,
2003) would prevent growth suppression of the tumor cell
itself.
At first glance, our data may seem in contrast to a recent
study by Berger et al. (2005), which proposed that CTCL is
owing to a malignant proliferation of CD4þCD25þ
regulatory T cells. The main difference between our studies
is that we investigated the phenotype and suppressive
function of peripheral CD4þCD25þ T cells ex vivo,
whereas Berger et al. used an in vitro model to mimic
potential interactions between epidermal Sezary cells and
immature dendritic cellsin the skin. It is possible though to
reconcile the findings of these two studies: Berger et al.
postulated that in the early stages of CTCL, CD4þ T cells in
Pautrier microabscesses within the epidermis encounter
Langerhans cells presenting apoptotic cell fragments, and
that this continuous stimulation leads to the induction and
expansion of tumor cells as Tregs. These tumor-derived Tregs
then prevent the induction of effective antitumor immunity by
inhibiting cytotoxicity by CD8þ T cells (Piccirillo and
Shevach, 2001). This allows the malignant CD4þ T cells
to persist in the skin and migrate into the lymph nodes and
www.jidonline.org 2221
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peripheral blood (Bunn et al., 1981). Subsequently, with
increasing tumor burden, additional changes develop such as
decreased TCR complexity in the normal T cells and reduced
tumor IL-2 responsiveness. Further disease progression may
then occur owing to dysregulation of Treg function in the
periphery, as shown in this current study. Nevertheless, it may
be possible that these peripheral blood tumor cells can still
retain the capacity to develop functional Treg activity if they
receive the correct in vitro signals as suggested by Berger et al.
Although we have shown that CD4þCD25þ FOXP3þ
T-cell presence and function may be dysregulated in CTCL
patients with a high tumor burden, it is still unclear whether
or not these dysfunctional Tregs are tumor-derived and
exactly what the pathogenic consequences are. There are an
increasing number of targeted therapies being used in CTCL,
such as Denileukin Difitox (diptheria-IL-2 fusion toxin) and
HuMaxCD4, but the consequences of the dysregulation of
Tregs in late stages of CTCL for therapeutic intervention
remain to be established.
MATERIALS AND METHODS
Patients
Ten patients (mean age 6472 years, men/women 7/3) fulfilled the
criteria for a diagnosis of CTCL. Clinical and immunophenotypic
features included erythroderma, pruritus, and lymphadenopathy. All
patients were treated with extracorporeal photopheresis, some in
combination with Targretin (Bexarotene) or Interferon alpha2B (see
Table 1). The percentage of Sezary cells in the lymphocyte
population was estimated by counting the number of atypical
lymphocytes with cerebriform nuclei (Sezary cells) in blood smears,
by one expert individual as described (Russell-Jones and Whittaker,
2000). All patients were human T-lymphotropic virus type I-
negative. The study was conducted according to the Declaration
of Helsinki Principles. The study was approved by the Guy’s and St
Thomas Ethics Committee, and participants were recruited to the
study with informed written consent. Ethical approval for the use
of phosphate buffer from sex-matched HCs (mean age 3873 years)
was obtained from the King’s College London Research Ethical
Committee.
Cell isolation and purification
Peripheral blood mononuclear cells (PBMCs) were obtained from
CTCL patients and HC using density gradient centrifugation
(Lymphoprep, Norway). CD4þ T cells were isolated by magnetic
cell sorting (495% purity) using a T-cell isolation kit (Miltenyi
Biotec, Germany) and subsequently the CD4þCD25þ T cells were
separated from the CD4þCD25 T cells with anti-CD25 microbe-
ads (Miltenyi Biotec) (Taams et al., 2001, 2002). Purity of the cell
subsets was confirmed by flow cytometry (representative example
shown in Figure 2a) and real-time PCR (see Figure 2b). The mean
fluorescence intensity of CD25 in the purified CD4þCD25þ T-cell
subsets was 2173 and 26711 in HCs and CTCLs, respectively.
Flow cytometry
Total lymphocyte counts were determined by flow cytometry by the
hospital immunology services. For phenotypic analysis, PBMCs were
stained with mAbs to CD4 (PC5-labelled, Beckman Coulter, UK) and
CD25 (PE-labelled, Miltenyi Biotec). Viable CD4þ T cells were
gated on forward scatter/side scatter profile and high expression of
CD4. The percentage of CD4þCD25þ total and CD4þCD25þ bright
T cells was determined as shown in Figure 1b.
Proliferation and suppression assays
Cells were cultured in RPMI-1640 medium, supplemented with 1%
penicillin/streptomycin, 1% glutamine, and 10% heat-inactivated
fetal calf serum. To assess anergy, CD4þCD25 or CD4þCD25þ
T cells (1 105/well) were cultured with irradiated autologous
PBMC as APC (1 105/well) and 50 ng/ml anti-CD3 mAb (OKT3,
Ortho Biotech, Bridgewater, VA). To assess suppressive activity,
CD4þCD25 T cells were cultured with or without CD4þCD25þ
T cells (1 105/well). For allogeneic assays, a similar experimental
setup was used, but responder cells were stimulated with allogeneic
APC and anti-CD3 (2 ng/ml) mAb in the absence or presence of
allogeneic suppressor cells. Cells were cultured for 3 days
(autologous assay) or 7 days (allogeneic assay), and during the last
18 hours of culture, [3H]-TdR was added at 1mCi/well (Amersham,
UK). Proliferative responses are expressed as the mean [3H]-TdR
incorporation (c.p.m.) of triplicate wells7SEM. Percent suppression
was calculated as (proliferation of CD4þCD25 T cells in the
presence of CD4þCD25þ T cells/proliferation of CD4þCD25
T cells in the absence of CD4þCD25þ T cells) 100%. Functional
analysis of samples from patients and HCs was performed in
parallel.
Quantitative real-time reverse transcription-PCR
RNA extraction and real-time PCR analysis was performed as
described previously (Mitchell et al., 2003). PCR primers and
fluorogenic probes for the target genes and endogenous controls
were purchased as TaqMans Gene Expression AssayTM (ABI).
The assay numbers for the endogenous control (cyclophilin)
and target genes were as follows: Hs99999904_ml (cyclo-
philin), Hs00166229_m1 (CD25), Hs00203958_m1 (FoxP3),
Hs00175480_m1 (CTLA-4), and Hs00192406_m1 (T-plastin).
Statistics
A Mann–Whitney U-test was used to investigate functional or
phenotypic differences between cells from HCs and non-suppressive
or suppressive CTCL patients. The Wilcoxon test was used to test
differences in the relative mRNA expression of the various genes
between the CD25 and CD25þ T-cell subsets. Correlations
between disease severity markers and suppressive activity by
CD4þCD25þ T cells were calculated with the Spearman’s r
method.
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